Cutaneous toxicity as a predictive biomarker for clinical outcome in patients receiving anticancer therapy

•There is an association between clinical outcomes and development of cutaneous toxicities due to anticancer therapeutics.•Vitiligo, rash, nail toxicity, or alopecia induced by anticancer therapeutics may be potential biomarkers in predicting treatment efficacy.•Identification of cutaneous toxicities may be an early and non-invasive way to determine cancer treatment efficacy.